Patisiran (ONPATTRO®), the first Food and Drug Administration (FDA) approved LNP-formulated siRNA drug, has reduced the formation of transthyretin protein in the liver and has been used to treat hereditary transthyretin-mediated amyloidosis since 2018. This evidence concerns the gene TTR and amyloidosis.